Tiny Dissolving Particles Could Spare Millions From Knee Replacement Surgery

A New Option for People Stuck Between Pills and Surgery

For millions of people with knee osteoarthritis, treatment options often fall into an uncomfortable middle ground: medications and injections may no longer provide enough relief, while joint replacement surgery can be too risky, undesirable, or premature. Now, a new study published in the journal Radiology is offering a compelling third path — one that requires no scalpel, no artificial joint, and no lengthy recovery.

In a study involving 194 patients, researchers found that a treatment using tiny particles that dissolve within hours was associated with substantial reductions in knee pain and improvements in mobility, with benefits persisting for at least 12 months — and 80% of patients reporting clinically meaningful pain relief at the one-year follow-up. The findings are drawing serious attention from the medical community as one of the most promising non-surgical advances for arthritis pain in years.

How the Procedure Actually Works

The approach, known as genicular artery embolization (GAE), aims to interrupt the inflammation and abnormal blood vessel growth that contribute to chronic knee pain. Rather than replacing the damaged joint, doctors use a thin catheter to deliver microscopic particles directly into specific blood vessels. As those vessels multiply in an arthritic knee, they contribute to inflammation and encourage the growth of sensory nerves involved in transmitting pain.

Researchers proposed that GAE performed with rapidly resorbable gelatin-based microspheres could combine the advantages of both temporary embolic materials and permanent microspheres while avoiding some of their drawbacks — and these specially designed spherical particles are calibrated by size and dissolve within hours. The technique is called superselective embolization because doctors target specific small arteries rather than blocking circulation throughout the joint, and it does not require an open surgical incision or replacement of the knee.

What the Numbers Actually Show

The study followed 194 people with knee pain related to osteoarthritis — 114 women and 80 men — with a median age of 69. The pain reduction was dramatic and measurable. The median pain score on a numeric rating scale decreased from 7 at baseline to 3 at 12 months, corresponding to a median reduction of 4 points. That's a shift from severe, life-limiting pain to a level most patients describe as manageable.

All procedures were technically successful with no moderate or severe adverse events and only mild, self-limited reactions in 6.7% of the study group. Transient skin discoloration occurred after 15 procedures, and one participant developed a superficial groin hematoma, all of which resolved without lasting effects. Lead researcher Dr. Florian Nima Fleckenstein of Charité – Universitätsmedizin Berlin noted that beyond pain, "we saw a significant drop in pain and a significant increase in function, including sports and recreation and daily activity," adding that "most , their quality of life significantly increased."

Promising, But the Full Picture Is Still Emerging

Study leader Fleckenstein noted that "for many patients with knee osteoarthritis, there is a real treatment gap today," explaining that conservative measures such as intra-articular injections no longer provide sufficient relief for many patients, but joint replacement is not an option for medical or personal reasons. GAE is designed specifically for that population — people who have exhausted standard treatments but aren't ready or able to go under the knife.

A randomized, sham-controlled study published in European Radiology in April 2026 followed 58 patients for 12 months and found that both the GAE and sham treatment groups experienced sustained reductions in pain, but researchers found no statistically significant difference between them — and MRI examinations also failed to identify a significant reduction in joint inflammation attributable to embolization. That study serves as a reminder that larger, more controlled trials are still needed. Still, significant pain reductions may be sustained in patients for at least two years following a single GAE procedure — a durability that, if confirmed at scale, could fundamentally reshape how doctors approach one of the most common and debilitating conditions of aging.